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ABSTRACT  
Fast dissolving tablet technology is a topic of current interest in pharmacy and therapeutics.  
Tablet swallowing difficulty primarily affects the geriatric and paediatric populations whereas unpalatable taste of drugs leads to patient non-
compliance. Swallowing problems also are common in young individuals because of their underdeveloped muscular and nervous systems. Fast 
Dissolving Tablets (FDTs) are one of the fruitful results of continuous technological advancements in the pharmaceutical industry. FD tablets play a 
major role in improving the patient’s compliance. A variety of drugs can be administered in the form of FD tablets as they give the advantage of the 
liquid medication in the solid preparation. These novel types of dosage forms have found acceptance among the geriatric, paediatric and dysphasic 
patients. Fast-Dissolving Tablet (FDT) is a tablet that dissolves or disintegrates in the oral cavity without the need of water or chewing. It has been 
developed for oral administration, also called as fast-melt, rapid-melts, porous tablets or fast disintegrating or orally disintegrating tablets (FDTs). 
Fast or mouth dissolving tablets have been formulated for paediatric, geriatric, and bedridden patients and for active patients who are busy and 
travelling and may not have access to water. Such tablets readily dissolve or disintegrate in the saliva generally within <60 seconds. Fast dissolving 
tablets can be prepared by various conventional methods like direct compression, wet granulation, moulding, spray drying, freeze drying, Cotton 
Candy Process and sublimation. In 1986, the first lyophilized fast-dissolving technology Zydis® was introduced (By Cardinal formerly R. P. Scherer) 
and several technologies are still improving. 
Keywords: Fast dissolving tablets, Patented technologies, Development approaches, Taste masking approaches, Mechanism of disintegration, 
Future prospects and research trends. 
 
INTRODUCTION 
Patient compliance is one of the most important aspects in the 
pharmacy practice. Now days, pharmacy companies are coming up 
with development of new drug delivery systems to ensure the 
delivery of the drugs to the patients efficiently and with fewer side 
effects. Solid dosage forms are popular because of ease of 
administration, accurate dosage, self-medication, pain avoidance and 
most importantly the patient compliance. The most popular solid 
dosage forms are being tablets and capsules; one important 
drawback of this dosage forms for some patients, is the difficulty to 
swallow. Drinking water plays an important role in the swallowing 
of oral dosage forms. Often times people experience inconvenience 
in swallowing conventional dosage forms such as tablet when water 
is not available, in the case of the motion sickness (kinetosis) and 
sudden episodes of coughing during the common cold, allergic 
condition and bronchitis. For these reason, tablets that can rapidly 
dissolve or disintegrate in the oral cavity have attracted a great deal 
of attention. This objective led to the emergence of the concept of 
Fast Dissolving Tablets. A fast-dissolving drug delivery system, in 
most cases, is a tablet that dissolves or disintrigrants in the oral 
cavity without the need of water or chewing. Oral routes of drug 
administration have wide acceptance up to 50-60% of total dosage 
forms. Their growing importance was underlined recently when 
European pharmacopoeia adopted the term “Orodispersible tablet” 
as a tablet that to be placed in the mouth where it disperses rapidly 
before swallowing. [1] 
Orodispersible tablets are not only indicated for people who have 
swallowing difficulties, but also are ideal for active people. Fast 
dissolving tablets are those when put on tongue disintegrate 
instantaneously releasing the drug which dissolve or disperses in 
the saliva. The faster the drug into solution, quicker the absorption 
and onset of clinical effect. It has been reported that dysphagia 
(difficulty in swallowing) is common among all age groups and more 
specific with paediatric, geriatric population along with 
institutionalized patients and patients with nausea, vomiting, and 
motion sickness complications. FDTs with good taste and flavour 
increase the acceptability of bitter drugs by various groups of 
population.  
The role of technologies related to formulation of effective drug 
delivery systems with enhanced patient compliance is unique and 
fascinating. Over the long period of time, it has been observed that 
more than 50 percent of Pharmaceutical products are orally 
administered for several reasons; many of these products contain 
drugs which have an unpleasant taste, often very bitter. The major 
consequence of the bitter taste is to restrict greatly the further 
development of oral preparations and clinical applications of these 
drugs. Along with the continuing improvement in the social standard 
of living, it is no longer acceptable for useful medicines to have bitter 
taste. [2] People supposed to take effective drugs that have a nice 
taste and can be administered easily. Accordingly, it is important to 
mask the unpalatable taste of a drug in order to improve the product 
quality. This will also increase the value of the finished product as 
well as patient compliance, especially where infants, children and 
elderly are concerned. Hence, Pharmaceutical Industries invest time, 
money and resources into developing palatable and pleasant tasting 
products and Industries also adopt various taste masking techniques 
to develop an appropriate formulation.  
FDTs offer several advantages over other dosage forms like 
effervescent tablets, dry syrups and chewing gums/tablets, which 
are commonly used to enhance patient’s compliance. Administering 
effervescent tablets/granules and dry syrups involve unavoidable 
preparation that include the intake of water. Elderly patients cannot 
chew large pieces of tablets or gums and sometimes experience the 
bitter or unpleasant taste of the drug in the dosage form, if the taste 
masking coat ruptures during mastication. [3] Administration of an 
oral drug delivery system having bitter taste and acceptable level of 
palatability has always been challenge in developing a formulation 
for paediatric and geriatric purpose. The bitterness of drug or drug 
product is minimized or eliminated by various physical, chemical 
and physiological means such as use of flavours, sweeteners, amino 
acids; and by using various techniques such as lipophilic vehicles, 
coating, inclusion complexation, ion exchange, effervescent agents, 
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rheological modification, solid dispersion system, group alteration 
and prodrug approach, freeze drying process, wet spherical 
agglomeration technique and continuous multipurpose melt 
technology. Developing a formulation with pleasant taste and rapid 
patient compliance has leaded the Pharmaceutical sector to work 
with newer and effective techniques for taste masking and product 
development. Therefore, formulation of taste masked products is 
challenge to Pharmacists. 
The basic approach in development of FDT is the use of 
superdisintegrants like cross linked carboxymethyl cellulose 
(croscarmellose), sodium starch glycolate (primogel, explotab), 
polyvinylpyrollidone (polyplasdone) etc, which provide 
instantaneous disintegration of tablet after putting on tongue, their 
by release the drug in saliva. The bioavailability of some drugs may 
be increased due to absorption of drug in oral cavity and also due to 
pregastric absorption of saliva containing dispersed drugs that pass 
down into the stomach. More ever, the amount of drug that is 
subjected to first pass metabolism is reduced as compared to 
standard tablet. [4] Fast dissolving Tablets which may release these 
drugs in the mouth are very promising for the delivery of high 
molecular weight protein and peptide.  
The technologies used for manufacturing fast-dissolving tablets are 
freeze-drying, spray-drying, tablet molding, sublimation, sugar-
based excipients, tablet compression, and disintegration addition. As 
a result of increased life expectancy, the elderly constitute a large 
portion of the worldwide population today. Earlier reports revealed 
that 26% out of 1576 patients experienced difficulty in swallowing 
tablets due to their large size, followed by their surface, shape and 
taste. The problem of swallowing tablets is also evident in travelling 
patients who may not have ready access to water. [5] 
Definition [6] 
The Center for Drug Evaluation and Research (CDER), US FDA 
defined Oral Disintegrating Tablets (ODT) as “A solid dosage form 
containing medicinal substances or active ingredient which 
disintegrates rapidly, usually within a matter of seconds, when 
placed upon the tongue”.  
 A fast dissolving tablet can be defined as a solid dosage form that 
can disintegrates into smaller granules which slowly dissolve in the 
mouth. The disintegration time for fast dissolving tablet varies from 
a few seconds to more than a minute depending on the formulation 
and the size of the tablet.  
 A fast disintegrating or dissolving system or tablet can be defined 
as a solid dosage form that can disintegrate or dissolve within 30 
seconds, in the oral cavity resulting in a solution or suspension 
without administration of water.  
 The fast disintegrating tablets are synonymous with fast 
dissolving tablets; melt in mouth tablets, rapid melts, Porous tablets, 
Orodispersible, quick dissolving or rapidly disintegrating tablets.  
Criteria for Fast dissolving Drug Delivery System: [7]  
The tablets should 
 Not require water to swallow, but it should dissolve or 
disintegrate in the mouth in matter of seconds. 
 Be compatible with taste masking. 
 Be portable without fragility concern. 
 Have a pleasant mouth feel. 
 Leave minimum or no residue in the mouth after oral 
administration. 
 Exhibit low sensitive to environmental condition as temperature 
and humidity. 
 Allow the manufacture of the tablet using conventional processing 
and packaging equipments at low cost. 
 Ease of Administration to the patient who cannot swallow, such as 
the elderly, stroke victims, bedridden patients, patient affected by 
renal failure and patient who refuse to swallow such as paediatric, 
geriatric & psychiatric patients. 
 No need of water to swallow the dosage form, which is highly 
convenient feature for patients who are travelling and do not have 
immediate access to water. 
 Rapid dissolution and absorption of the drug, which will produce 
quick onset of action. 
 Some drugs are absorbed from the mouth, pharynx and 
esophagus as the saliva passes down into the stomach. In such cases 
bioavailability of drug is increased. 
 Pregastric absorption can result in improved bioavailability and 
as a result of reduced dosage; improve clinical performance through 
a reduction of unwanted effects. 
 Good mouth feel property helps to change the perception of 
medication as bitter pill particularly in pediatric patient. 
 The risk of chocking or suffocation during oral administration of 
conventional formulation due to physical obstruction is avoided, 
thus providing improved safety. 
 New business opportunity like product differentiation, product 
promotion, patent extensions and life cycle management. 
 Beneficial in cases such as motion sickness, sudden episodes of 
allergic attack or coughing, where an ultra rapid onset of action 
required. 
 An increased bioavailability, particularly in cases of insoluble and 
hydrophobic drugs, due to rapid disintegration and dissolution of 
these tablets. 
 Stability for longer duration of time, since the drug remains in 
solid dosage form till it is consumed. So, it combines advantage of 
solid dosage form in terms of stability and liquid dosage form in 
terms of bioavailability. 
Benefits of fast dissolving tablets [8] 
 Administered without water, anywhere, any time. 
 Suitability for geriatric and paediatric patients, who experience 
difficulties in swallowing and for the other groups that may 
experience problems using conventional oral dosage form, due to 
being mentally ill, the developmentally disable and the patients who 
are un-cooperative, or are on reduced liquid intake plans or are 
nauseated. 
 Beneficial in cases such as motion sickness, suede episodes of 
allergic attack or coughing, where an ultra rapid onset of action 
required. 
 An increased bioavailability, particularly in cases of insoluble and 
hydrophobic drugs, due to rapid disintegration and dissolution of 
these tablets. 
 Stability for longer duration of time, since the drug remains in 
solid dosage form till it is consumed. So, it combines advantage of 
solid dosage form in terms of stability and liquid dosage form in 
terms of bioavailability. 
 FDT passes all the advantages of solid dosage forms like good 
stability, easy manufacturing, unite and accurate dosing, easy 
handling etc. 
 Provides rapid drug therapy intervention. 
 There is no risk of physical obstruction due to dosage form. 
 The possibility of an improved bioavailability due to rapid 
absorption and faster onset of action. 
 Ease of administration to patients who are unable or refuse to 
swallow a tablet, such as paediatric, geriatric and psychiatric and 
disabled patients. 
 Ability to provide advantages of liquid medication in the form of 
solid preparation. 
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 Can be designed to leave minimal or no residue in the mouth after 
administration and also to provide a pleasant mouth feel. 
 Allows high capacity of drug loading. 
 FDTs helps avoids hepatic metabolism by allowing pregastric 
drug absorption thus reducing the dose of drug required. 
 Adaptable to existing processing and packaging machinery. 
 Cost-effective. 
 Gives accurate dosing as compared to liquids Free of need of 
measuring, an essential drawback in liquids. 
 Provides new business opportunities such as, 
a. Product differentiation, 
b. Line extension and life-cycle management, 
c. Exclusivity of product promotion and patent-life extension. 
Limitations of Mouth Dissolving Tablets [8] 
• The tablets usually have insufficient mechanical strength. Hence, 
careful handling is required. 
• The tablets may leave unpleasant taste and/or grittiness in mouth 
if not formulated properly. 
• Drugs with relatively larger doses are difficult to formulate into 
MDT e.g. antibiotics like amoxicillin with adult dose tablet containing 
about 500 mg of the drug. 
• Patients who concurrently take anticholinergic medications may 
not be the best candidates for MDT. 
• Similarly patients with Sjogren’s syndrome or dryness of the 
mouth due to decreased saliva production may not be good 
candidates for these tablet formulations. 
Patented technologies for fast dissolving tablets 
Nowadays FD tablets are successfully evolved as the alternative way 
of administering tablets. There are number of patented technologies 
which were developed for the formation of FD tablets and are 




Flash Dose Technology 
Wow Tab Technology 




Shearform Technology.  






Zydis Technology: [9] 
Zydis, the best known of the mouth-dissolving/disintegrating tablet 
preparations was the first marketed new technology tablet. Zydis 
formulation is a unique freeze dried tablet in which drug is 
physically entrapped or dissolved within the matrix of fast 
dissolving carrier material. When zydis units are put into the mouth, 
the freeze-dried structure disintegrates instantaneously and does 
not require water to aid swallowing. The zydis matrix is composed 
of many material designed to achieve a number of objectives. To 
impart strength and resilience during handling, polymers such as 
gelatine, dextran or alginates are incorporated. These form a glossy 
amorphous structure, which imparts strength. To obtain 
crystallinity, elegance and hardness, saccharide such as mannitol or 
sorbitol are incorporated. Water is used in the manufacturing 
process to ensure production of porous units to achieve rapid 
disintegration while various gums are used to prevent 
sedimentation of dispersed drug particles in the manufacturing 
process. Collapse protectants such as glycine prevent the shrinkage 
of zydis units during freeze-drying process or long-term storage. 
Zydis products are packed in blister packs to protect the formulation 
from moisture in the environment. A Zydis tablet is produced by 
lyophilizing or freeze-drying the drug in a matrix usually consisting 
of gelatine. The product is very lightweight and fragile and must be 
dispensed in a special blister pack. The Zydis product is made to 
dissolve on the tongue in 2 to 3 seconds. A major claim of the Zydis 
product is increased bioavailability compared to traditional tablets. 
Because of its dispersion and dissolution in saliva while still in the 
oral cavity, there can be a substantial amount of pre-gastric 
absorption from this formulation. Any pre-gastric absorption avoids 
first-pass metabolism and can be an advantage in drugs that 
undergo a great deal of hepatic metabolism. There are some 
disadvantages to the Zydis technology. As mentioned earlier, the 
Zydis formulation is very lightweight and fragile and therefore 
should not be stored in backpacks or the bottom of purses. Finally, 
the Zydis formulation has poor stability at higher temperatures and 
humidities. It readily absorbs water and is very sensitive to 
degradation at humidities greater than 65%. The Zydis technology 
(ZT) is a patented technique which had been used for drugs like 
famotidine, enalapril, loperamide, piroxicam, oxazepam, lorazepam, 
domeperidone, brompheniramine, olanzepine, ondansetron and 
rizatriptan. In U.S., the FDT products available are: Claritin Reditab, 
Dimetapp Quick Dissolve, Feldene Melt, Maxalt-MLT, Pepcid RPD, 
Zofran ODT and Zyprexa Zydis. 
Durasolv Technology: [10] 
Durasolv is the patented technology of CIMA lab's second-generation 
mouth-dissolving/disintegrating tablet formulation. Durasolv is an 
appropriate technology for product requiring low amounts of active 
ingredients. The tablets made by this technology consist of drug, 
filler and a lubricant. Tablets are prepared by using conventional 
tabletting equipment and have good rigidity (friability less than that 
2%). These can be packaged into conventional packaging system like 
blisters, pouches or vials. DuraSolv is Cima Produced in a fashion 
similar to OraSolv; DuraSolv has much higher mechanical strength 
than its predecessor due to the use of higher compaction pressures 
during tabletting. The DuraSolv product is thus produced in a 
mouther and more cost-effective manner. One disadvantage of 
DuraSolv is that the technology is not compatible with larger doses 
of active ingredients, because the formulation is subjected to such 
high pressures on compaction.  
Orasolv Technology: [10] 
CIMA labs have developed Orasolv Technology. In this system active 
medicament is taste masked. It also contains effervescent 
disintegrating agent. Tablets are made by direct compression 
technique at low compression force in order to minimize oral 
dissolution time. Conventional blenders and tablet machine is used 
to produce the tablets. The tablets produced are soft and friable. 
OraSolv was Cima's first mouth-dissolving/disintegrating dosage 
form. The OraSolv technology, unlike Zydis, disperses in the saliva 
with the aid of almost imperceptible effervescence. The OraSolv 
technology is best described as a mouth disintegrating tablet; the 
tablet matrix dissolves in less than one minute, leaving coated drug 
powder. The OraSolv tablet has the appearance of a traditional 
compressed tablet. However, the OraSolv tablets are only lightly 
compressed, yielding a weaker and more brittle tablet in comparison 
with conventional tablets. For that reason, Cima developed a special 
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handling and packaging system for OraSolv. An advantage that goes 
along with the low degree of compaction of OraSolv is that the 
particle coating used for taste masking is not compromised by 
fracture during processing. These formulations can accommodate 
single or multiple active ingredients and tablets containing more 
that 1.0 g of drug have been developed. Their disintegration time is 
less than 30 seconds. The OraSolv formulations are not very 
hygroscopic. The major disadvantage of the OraSolv formulations is 
its mechanical strength. 
Flash Dose Technology: 
Flash dose technology has been patented by FUISZ. Nurofen meltlet, 
a new form of ibuprofen as melt in mouth tablets prepared using 
flash dose technology is the first commercial product launched by 
Biovail Corporation. Flash dose tablets consist of self-binding 
shearform matrix termed as “floss”. Shear form matrices are 
prepared by flash heat processing. The Flash Dose technology 
utilizes a unique spinning mechanism to produce a floss-like 
crystalline structure, much like cotton candy. This crystalline sugar 
can then incorporate the active drug and be compressed into a 
tablet. The final product has a very high surface area for dissolution. 
It disperses and dissolves quickly once placed onto the tongue.  
Wow tab Technology: [11] 
Wow tab technology is patented by Yamanouchi Pharmaceutical Co. 
WOW means “Without Water”. In this process, combination of low 
Mouldability saccharides (rapid dissolution) and high Mouldability 
saccharides (good binding property) (eg. Maltose, oligosaccharides) 
are used to obtain an adequate hardness and rapidly melting strong 
tablet. The active ingredient is mixed with a low mouldability 
saccharide (eg. lactose, glucose, and mannitol) and granulated with a 
high mouldability saccharide and compressed into table. The Wow 
tab mouth-dissolving/disintegrating tablet formulation has been on 
the Japanese market from a number of years. The Wowtab 
technology utilizes sugar and sugar-like (eg. mannitol) excipients. 
Due to its significant hardness, the Wowtab formulation is a bit more 
stable to the environment than the Zydis or OraSolv. It is suitable for 
both conventional bottle and blister packaging. The Wowtab product 
dissolves quickly in 15 seconds or less.  
Flash tab Technology: [12] 
Prographarm laboratories have patented the Flash tab technology. 
Tablet prepared by this system consists of an active ingredient in the 
form of microcrystals. Drug microgranules may be prepared by 
using the conventional techniques like coacervation, micro 
encapsulation, simple pan coating methods and extrusion 
spheronisation. All the processing utilized conventional tabletting 
technology. The microcrystals of microgranules of the active 
ingredient are added to the granulated mixture of excipients 
prepared by wet or dry granulation, and compressed into tablets. 
The tablets produced are reported to have good mechanical strength 
and disintegration time less than one minute.  
Oraquick Technology [12] 
The Oraquick mouth-dissolving/disintegrating tablet formulation 
utilizes a patented taste masking technology. The taste masking 
process does not utilize solvents of any kind, and therefore leads to 
mouther and more efficient production. Also, lower heat of 
production than alternative mouth-dissolving/disintegrating 
technologies makes Oraquick appropriate for heat-sensitive drugs. 
KV Pharmaceutical claims that the matrix that surrounds and protects 
the drug powder in microencapsulated particles is more liable (tablets 
can be compressed to achieve significant mechanical strength without 
disrupting taste masking) Oraquick claims quick dissolution in a matter 
of seconds, with good taste-masking. There are no products using the 
Oraquick technology currently on the market, but KV Pharmaceutical has 
products in development such as analgesics, scheduled drugs, cough and 
cold, psychotropic, and anti-infectives.  
Quick–Dis Technology 
The novel intra-oral drug delivery system, trademarked as Quick-
Dis™, is Lavipharm’s proprietary patented technology and is a thin, 
flexible, and quick-dissolving film. When the film is placed on the top 
or the floor of the tongue. It is retained at the site of application and 
rapidly releases the active agent for local and/or systemic 
absorption. The typical disintegration time is only 5 to 10 seconds 
for the Quick-Dis™ film with a thickness of 2 mm.  
NanoCrystal Technology [13] 
For mouth dissolving tablets, Elan's proprietary NanoCrystal 
technology can enable formulation and improve compound activity 
and final product characteristics. Decreasing particle size increases 
the surface area, which leads to an increase in dissolution rate. This 
can be accomplished predictably and efficiently using NanoCrystal 
technology. NanoCrystal particles are small particles of drug 
substance, typically less than 1000 nm in diameter, which are 
produced by milling the drug substance using a proprietary wet 
milling technique. NanoCrystal colloidal dispersions of drug 
substance are combined with water-soluble ingredients, filled into 
blisters and lyophilized. The resultant wafers are remarkably robust, 
yet dissolve in very small quantities of water in seconds.  
Shearform Technology TM
The Shearform technology is based on preparation of floss that is 
also known as ‘shearform matrix’, which is produced by subjecting a 
feedstock containing a sugar carrier by flash heat processing. In this 
process, the sugar is simultaneously subjected to centrifugal force 
and to a temperature gradient, which raises the temperature of the 
mass to create an internal, flow condition, which permits part of it to 
move with respect of the mass. The flowing mass exists through the 
spinning head that flings the floss. The floss so produced is 
amorphous in nature so it is further chopped and recrystalised by 
various techniques to provide uniform flow properties and thus 
facilitate blending. The recrystalised matrix is then blended with 
other tablet excipients and an active ingredient. The resulting 
mixture is compressed into tablet. The active ingredient and other 
excipients can be blended with floss before carrying out 
recrystallisation. The shearform floss, when blended with the coated 
or uncoated microspheres, is compressed into Flashdose or EZ chew 
tablets on standard tabletting equipment.  
 [13] 
Ceform Technology 
In Ceform technology microspheres containing active 
pharmaceutical ingredient are prepared. The essence of ceform 
microsphere manufacturing process involves placing a dry powder, 
containing substantially pure drug material or a special blend of 
drug materials plus other pharmaceutical compounds, and 
excipients into a precision engineered and rapidly-spinning 
machine. The centrifugal force of the rotating head of ceform 
machine throws the dry drug blend at high speed through small, 
heated openings. The carefully controlled temperature of the 
resultant microburst of heat liquefies the drug blend to form a 
sphere without adversely affecting drug stability. The microspheres 
are then blended and/or compressed into the pre-selected oral 
delivery dosage format. The ability to simultaneously process both 
drug and excipient generates a unique microenvironment in which 
materials can be incorporated into the microsphere that can alter 
the characteristics of the drug substance, such as enhancing 
solubility and stability. The microspheres can be incorporated into a 
wide range of fast dissolving tablets such as Flashdose, EZ chew, 
Spoon Dose as well as conventional tablets. [14] 
TM  
Pharmaburst technology [14] 
SPI Pharma, New castle, patents this technology. It utilizes the 
coprocessed excipients to develop ODT, which dissolves within 30-
40 s. This technology involves dry blending of drug, flavour, and 
lubricant followed by compression into tablets. Tablets obtained 
have sufficient strength so they can be packed in blister packs and 
bottles.  
Frosta technology [15] 
Akina patents this technology. It utilizes the concept of formulating 
plastic granules and coprocessing at low pressure to produce strong 
tablets with high porosity. Plastic granules composed of:  
 Porous and plastic material  
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 Water penetration enhancer, and Binder  
The process involves usually mixing the porous plastic material with 
water penetration enhancer and followed by granulating with 
binder. The tablets obtained have excellent hardness and rapid 
disintegration time ranging from 15 to 30s depending on size of 
tablet.  
Ziplet technology [15] 
In ziplet technology water insoluble drug(s) as coated micro 
particles are used. The addition of suitable amount of water soluble 
inorganic excipients combination with disintegrants are impart an 
excellent physical resistance to the FDT and simultaneously 
maintained optimal disintegration. The use of water soluble inorganic 
excipients offer better enhancement of disintegration in comparison to 
the most commonly used water soluble sugars or salts. Tablets primarily 
contain water soluble components often tend to dissolve rather than 
disintegrate and concentrated viscous solution is formed reduces the 
rate of water diffusion into the tablet core. 
Humidity treatment [15] 
The mechanical strength of some tablets increased substantially 
after moisture treatment, compared with the tablets before the 
treatment. The increase mechanical strength is due to the formation 
of liquid bridges in the presence of moisture and then formation of 
solid bridges after drying. When an amorphous sugar is treated to go 
through the humidification and drying process, it changes to a 
crystalline state. This change increases the tablet strength 
substantially. In a patent by Mizumoto et al a drug, a sugar, and an 
amorphous sugar capable of transforming from amorphous to 
crystalline state were mixed and compressed into tablets. The 
“amorphous sugar” is that which can form an amorphous state by 
spray drying, freeze drying, or other granulation methods. These 
amorphous sugars include glucose, lactose, maltose, sorbitol, 
trehalose, lactilol, and fructose. The relative humidity is determined 
by the apparent critical relative humidity of the mixture of a drug 
and an amorphous sugar. A relative humidity is greater than or 
equal to the critical relative humidity of this mixture which is to be 
chosen for the humidity condition. The advantage of using 
amorphous sugar is that they have low critical relative humidity, so 
that they can absorb water even at low moisture levels. If a high 
humidity condition is used, tablets may adhere together, causing 
manufacturing problems. 
Sintering [15] 
When thermal energy is applied to a powder compact, the compact 
is densified and the average grain size increases. The basic 
phenomena occurring during this process is called sintering or 
densification and grain growth. Lagoviyer et al disclosed a process 
that tablet strength can be increased by sintering the tablet 
components at high temperatures and then resolidifying them at 
lower temperatures. A bulk agent in this formulation is used to 
provide bulk volume to the overall tablet and suitable agents include 
carbohydrates, calcium carbonate, and magnesium carbonate. 
Solvents can be chosen from water, ethyl alcohol, isopropyl alcohol 
or a mixture thereof. Binders are water soluble polymers such as 
polyethylene glycol (PEG), with a molecular weight of approximately 
1000 to 1,000,000 Dalton. The granules are then lightly compressed 
to form tablets. These tablets are heated for a sufficient time and 
temperature to allow the binding agent to melt. The heating step is 
intended to melt the binding agent to create intra tablet bonds and 
helps to weld the product in to shape. Typically, a laboratory oven is 
set at around 50-100ºC. The heating time ranges from 3 to 45 
minutes. The binding agents are resolidified as the temperature is 
reduced to ambient temperature. The disintegration time is 
generally within 3-60 seconds. 
  
Table 1: List of Various Patented Technologies with their Company and Product Name [9- 10-15] 
Tech. Key attributes  methods  Company names Activ ingredients & Brand names  
Zydis®  Freeze-drying on-blister packing Lyophilization R. P. Scherer, Inc. 
[Cardinal Health]  
Loratidine (Claratin) ®Reditab 
Fanotidine Pepcid®ODT 
Selegiline ZelaparTM 
Rizatritpan benzoate Maxalt-®MLT 
Ondansetron Zofran®ODT 
Durasolv  Direct compression using water-
soluble excipients 





OraSolv  low compression force and an 
effervescent couple as a 
water-soluble disintegrating agent 
Direct Compression Cima Labs Inc. Paracetamol(Tempra Quicklets) 
Mirtazapine Remeron®SolTab 
TempraFirs Tablet 
Flashdose  - Cotton Candy Process Fuisz Technology Ltd. Tramadol HCL (Relivia Flashdose) 
Fluoxetine 
FluoxetineODT 
Zolpidem Tertrate Zolpidem ODT 
WOWTAB®  High- and low-moldability 
saccharides 
Direct Compression Yamanouchi Pharma Famotidine(Gaster D) 




Flashtab  Granulation of excipients by wet 
or dry granulation 
method and followed by 
compressing into tablets 
Direct Compression Ethypharm France. Ibuprofen(Nurofen Flashtab) 
Oraquick  Micromask Taste masking   K V Pharma. Co. Inc. Hyoscamine Sulfate ODT 
Quicksolv   Lyophilization Jansen Pharma Risperidone (Risperdal MTab) 
Pharmabrust  Direct compression of powder 
mixture 
 SPI Pharma  
Advatab  Direct compression using external 
lubrication system 
Microcaps & diffuscap 
CR Technology 
Eurand International  Advatab Cetrizine, 
 Advatab Paracetamol 
Lyoc  Freeze-drying on the shelves of 
freeze dryer 
Lyophilization Farmalyoc 
Laboratories L. Lafon, 




Directly compressible excipient 
system 
Direct Compression SPI Pharma  
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Techniques used formulation of fast dissolving tablets (FDTs)  
The fast dissolving property of the FDTs is attributed to quick 
ingress of water into tablet matrix resulting in rapid disintegration. 
Hence, the basic approaches to develop FDTs include: Maximizing 
the porous structure of the tablet matrix 
Incorporating the appropriate disintegrating agent/agents 
Using highly water soluble excipients in the formulation 
So far, several techniques have been developed on the basis of 
different principles.  
1. Freeze drying / lyophilization 
2. Tablet Moulding 
3. Spray drying 
4. Sublimation 
5. Direct compression 
6. Mass extrusion 
7. Cotton candy process 
8. Nanonization 
Freeze-Drying or Lyophilization: [16] 
Freeze drying is the process in which water is sublimed from the 
product after it is frozen. This technique creates an amorphous 
porous structure that can dissolve rapidly. The saliva goes into the 
matrix resulting in the dissolution of the matrix. The active drug is 
dissolved or dispersed in an aqueous solution of a carrier/polymer, 
such as suspending agents, wetting agents, preservatives, 
antioxidants, colours and flavours which improve the process 
characteristics or enhance the quality of final product. The mixture 
is done by weight and poured in the walls of the preformed blister 
packs. The trays holding the blister packs are passed through liquid 
nitrogen freezing tunnel to freeze the drug solution or dispersion. 
Then the frozen blister packs are placed in refrigerated cabinets to 
continue the freeze-drying. After freeze-drying the aluminium foil 
backing is applied on a blister-sealing machine. Finally the blisters 
are packaged and shipped. Essential characteristics for Freeze 
drying formulations include small particle size with low dose and 
water-insoluble, chemically stable drug molecule. The freeze-drying 
technique has demonstrated improved absorption and increase in 
bioavailability. The major disadvantages of lyophilization technique 
are that it is expensive and time consuming; fragility makes 
conventional packaging unsuitable for these products and poor 
stability under stressed conditions. This technique forms the basis of 
Zydis, Quicksolv and Lyoc technologies which are used to 
manufacture FDTs. Lyophilization is also used to develop an oral 
formulation that not only dissolved rapidly but also exhibited 
improved bioavailability of several drugs. 
The major advantage of this technology is that it offers less 
disintegration time but the technique is quite expensive and special 
packaging procedures are required. The storage conditions should 
be properly maintained as these tablets are less stable to changing 
environment; hence special packaging procedures are required. 
During lyophilization, formulation excipients and process variables 
play an important role. Hydrochlorothiazide was used as a model 
drug for detecting the influence of various formulations and process 
parameters on the characteristics of FD tablets. According to them, 
maltodextrins are useful for the formulation of tablets formed by 
lyophilisation technique. Similarly results revealed the role of 
formulation excipients in the development of lyophilised fast 
disintegrating tablets. It was concluded that the use of 5% gelatin in 
combination of mannitol is the ideal formulation. Carbopol 974P-NF 
and Pluronic F127 (6%) were concluded to have the best viscosity 
modifying properties. 
 
Table 2: Excipients and their uses in the manufacture of FDT using freeze drying technique [16] 
 Excipient   Use   Examples  
 Polymer   Strength and rigidity   Gelatine, alginate and dextrin   
 Polysaccharides   Crystallinity, hardness, and palatability   Mannitol and sorbitol   
 Collapse protectants   Prevents shrinking   Glycerine   
 Flocculating agents   Uniform dispersion   Xanthum gum and acacia   
 Preservatives   Prevent microbial and fungal growth   Parabens   
 Permeation enhancer   Tran mucosal permeability enhancer   Sodium lauryl sulphate   
 pH adjusters   Chemical stability   Citric acid and sodium hydroxide   
 Flavours and sweeteners   Patient compliance   -   
 Water   Porous unit formation   -   
 
Tablet Molding: [17] 
Molding process is of two type’s i.e. solvent method and heat 
method. The tablets manufactured in this manner are less compact 
than compressed tablets and posses a porous structure that hastens 
dissolution. The mechanical strength of molded tablets is a matter of 
great concern. Binding agents, which increase the mechanical 
strength of the tablets, need to be incorporated. Taste masking is an 
added problem to this technology. The taste masked drug particles 
were prepared by spray congealing a molten mixture of 
hydrogenated cottonseed oil, sodium carbonate, lecithin, 
polyethylene glycol and an active ingredient into a lactose based 
tablet triturate form. Compared to the lyophilization technique, 
tablets produced by the molding technique are easier to scale up for 
industrial manufacture. 
Following are the different tablet moulding techniques: 
a) Compression Moulding Process: Solvent method 
This manufacturing process involves moistening the powder blend 
with a hydro alcoholic solvent followed by pressing into mould 
plates to form a wetted mass (compression moulding). The solvent is 
then removed by air drying, a process similar to the manufacture of 
tablet triturates. Such tablets are less compact than compressed 
tablets and possess a porous structure that hastens dissolution. 
b) Heat-Moulding Process: 
Heat-moulding process involves setting the molten mass containing 
a dispersed drug. This process uses agar solution as a binder and a 
blister packaging well as a mould to manufacture the tablet. A 
suspension containing drug, agar and sugar is prepared followed by 
pouring the suspension into the blister packaging well, solidifying 
the agar solution at room temperature to form a jelly and finally 
drying at approximately 30°C under vacuum. 
c) Moulding by Vacuum Evaporation without Lyophilization: 
This process involves pouring of the drug excipient mixture (in the 
form of a slurry or paste) into a mould of desired dimension, 
freezing the mixture to form a solidified matrix and finally subjecting 
it to vacuum drying at a temperature within the range of its collapse 
temperature and equilibrium freezing temperature. This results in 
the formation of a partially collapsed matrix. This method differs 
from the lyophilization technique as in the former, the evaporation 
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of free unbound solvent occurs from a solid through the liquid phase 
to a gas, under controlled conditions, instead of the sublimation 
which takes place in the latter process. Unlike lyophilization, vacuum 
drying helps to densify the matrix and thereby improves the 
mechanical strength of the product. In comparison to lyophilisation 
process, tablets produced by moulding technique are easier to adapt 
to the industrial scale. Moulded tablets are cheaper and have poor 
mechanical strength. They can break or get eroded during the 
process of handling and storing. To overcome the poor taste, drug 
containing discrete particles was incorporated, which was formed 
by spray congealing a molten mixture of hydrogenated cottonseed 
oil, sodium bicarbonate, lecithin, polyethylene glycol and active 
ingredient into a lactose based tablet triturate form. 
Spray drying: [17-18] 
Spray drying process is widely used to provide products with high 
porosity in fine powder because the processing solvent can be easily 
dried. In this technique, gelatin can be used as a supporting agent 
and as a matrix, mannitol and lactose as a bulking agent and sodium 
starch glycolate or crosscarmellose or crospovidone and acidic 
ingredient (citric acid) and/or alkaline ingredients (e.g. sodium 
bicarbonate) are used as superdisintegrants. Tablets manufactured 
from the spray-dried powder have been reported to disintegrate in 
less than 20 seconds in aqueous medium. This spray-dried powder, 




Fig. 1: Flowchart for coating liquid and solid particles using spray-dry process [17] 
 
Sublimation: [18] 
To generate a porous matrix, volatile ingredients are incorporated in 
the formulation that is later subjected to a process of sublimation. 
Highly volatile ingredients like ammonium bicarbonate, ammonium 
carbonate, benzoic acid, camphor, naphthalene, urea, urethane and 
phthalic anhydride may be compressed along with other excipients 
into a tablet. This volatile material is then removed by sublimation 
leaving behind a highly porous matrix.  
Tablets manufactured by this technique have reported to usually 
disintegrate in 10-20 sec. Even solvents like cyclohexane; benzene 
can be used as pore forming agents. Sublimation of camphor was 
done in vacuum at 80 C for 30 minutes to develop pores in the 
tablets. Another technique describes use of water to produce fast 
dissolving tablets. Active ingredient and carbohydrates such as 
glucose or mannitol were moistened with water (1-3% w/w) and 




Fig. 2: Schematic Diagram of Sublimation Technique for Preparation of FDT [18] 
Sanket et al. 




Ex. Aceclofenac (NSAID), Amlodipine besylate (Dihydropyridine 
calcium antagonist), Ebastine (Second generation non–sedating H1 
receptor antagonist), Cinnarzine (Histamine H- receptor antagonist), 
prepared by sublimation method 
Direct Compression: [19-20] 
Direct compression represents the simplest and most cost effective 
tablet manufacturing technique. This technique can now be applied 
to preparation of FDT because of the availability of improved 
excipients especially superdisintegrants and sugar based excipients. 
(a) Superdisintegrants 
In many orally disintegrating tablet technologies based on direct 
compression, the addition of Superdisintegrants principally affects 
the rate of disintegration and hence the dissolution.  
The presence of other formulation ingredients such as water-soluble 
excipients and effervescent agents further hastens the process of 
disintegration. 
(b) Sugar Based Excipients 
This is another approach to manufacture FDT by direct compression. 
The use of sugar based 
excipients especially bulking agents like dextrose, fructose, isomalt, 
lactilol, maltilol, maltose, mannitol, sorbitol, starch hydrolysate, 
polydextrose and xylitol, which display high aqueous solubility and 
sweetness, and hence impart taste masking property and a pleasing 
mouthfeel. Mizumito et al have classified sugar-based excipients into 
two types on the basis of molding and dissolution rate. 
Type 1 saccharides (lactose and mannitol) exhibit low mouldability 
but high dissolution rate. 
Type 2 saccharides (maltose and maltilol) exhibit high mouldability 
and low dissolution rate. 
Similarly, the use of sugar-based recipients like dextrose, fructose, 
isomalt, lactilol, maltitol, maltose, mannitol, sorbitol, starch 
hydrolysate, polydextrose and xylitol is appreciated in masking the 
bad taste of the tablets and impart sweetness while formulating FD 
tablets. 
Examples of FDTs prepared by direct compression method: 
Albendazole (Broad spectrum antihelmintic), Chlorpromazine 
hydrochloride (Antiemetic), Aceclofenac (NSAID), Cetrizine 
Hydrochloride (Selective H1 receptor antagonist) Clonazepam 
(Antiepileptic), Etoricoxib (NSAID), Granisetron hydrochloride, 
Isoxsuprine hydrochloride (Vasodilator), Lornoxicam (NSAID), 
Losartan potassium (Antihypertensive), Levo-cetrizine 
hydrochloride ( Non sedative anti-histaminic), Meclizine 
hydrochloride (Antiemetic), Metoprolol tartrate (Antihypertensive), 
Naproxen (NSAID), Famotidine (Histamine H2- receptor antagonist), 
Montelukast sodium (Antineoplastic), Telmisartan 
(Antihypertensive), Repaglinide (Antidiabetic), Rosiglitazone 
maleate (Antidiabetic), Salbutamol sulphate (β2 receptor agonist). 
Mass-Extrusion: 
This technology involves softening of the active blend using the 
solvent mixture of water soluble polyethylene glycol and methanol 
and expulsion of softened mass through the extruder or syringe to 
get a cylindrical shaped extrude which are finally cut into even 
segments using heated blade to form tablets. This process can also 
be used to coat granules of bitter drugs to mask their taste. Ex. 
Rizatriptan benzoate (Serotonin 5-HT receptor agonist). 
Cotton Candy Process: [21] 
This method involves Shearform technology, use of a combined form 
of excipients, either alone or with drugs which are known as floss for 
preparation of matrix. The floss is a fibrous material similar to 
cotton-candy fibers, commonly made of saccharides such as sucrose, 
dextrose, lactose and fructose at temperatures ranging between 
180–266 °F.  
However, other polysaccharides such as polymaltodextrins and 
polydextrose can be transformed into fibers at 30–40% lower 
temperature than sucrose. This modification permits the safe 
incorporation of thermo labile drugs into the formulation. The 
tablets manufactured by this process are highly porous in nature 
and offer very pleasant mouth feel due to fast solubilization of 
sugars in presence of saliva. 
Nanonization 
A recently developed Nanomelt technology involves reduction in the 
particle size of drug to nanosize by milling the drug using a 
proprietary wet-milling technique. The nanocrystals of the drug are 
stabilized against agglomeration by surface adsorption on selected 
stabilizers, which are then incorporated into FDTs. This technique is 
especially advantageous for poorly water soluble drugs. Other 
advantages of this technology include fast disintegration/dissolution 
of nanoparticles leading to increased absorption and hence higher 
bioavailability and reduction in dose, cost effective manufacturing 
process, conventional packaging due to exceptional durability and 
wide range of doses (up to 200 mg of drug per unit). 
 
Table 3: List of Superdisintegrants [20] 
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Table 4: List of commercially available Fast dissolving tablets [17-19] 
S. No.   Trade Name   Active Drug   Manufacturer  
1.   Felden fast melt   Piroxicam   Pfiser Inc., NY, USA  
2.   Claritin redi Tab   Loratidine   Schering plough Corp., USA  
3.   Maxalt MLT   Rizatriptan   Merck and Co., NJ, USA  
4.   Zyprexia   Olanzapine   Eli lilly, Indianapolis, USA  
5.   Pepcid RPD   Famotidine   Merck and Co., NJ, USA  
6.   Zofran ODT   Ondansetron   Glaxo Wellcome, Middlesex, UK  
7.   Zoming-ZMT   Zolmitriptan   AstraZeneca, Wilmington, USA  
8.   Zeplar TM   Selegilline   Amarin Corp., London, UK  
9.   Tempra Quiclets   Acetaminophen   Bristol myers Squibb, NY, USA  
10   Febrectol   Paracetamol   Prographarm, Chateauneuf, France  
11   Nimulid MDT   Nimesulide   Panacea Biotech, New delhi, India  
12   Torrox MT   Rofecoxib   Torrent pharmaceuticals, India  
13   Olanex instab   Olanzapine   Ranbaxy lab. Ltd. New-delhi, India  
14   Romilast   Montelukast   Ranbaxy lab. Ltd. New-delhi, India  
15   Propulsid Quicksolv   Cisapride Monohydrate   Janssen pharmaceutics  
16   Risperdal MTab   Risperidone   Janssen pharmaceutics  
17   Spasfon Lyoc)   Phloroglucinol Hydrate   Farmalyoc  
18   Nurofen FlashTab  Ibuprofen   Ethypharm  
19   Tempra-Quicklets   Paracetamol   Cima Labs,Inc.  
20   Zolmig Repidmelt   Zolmitriptan   Cima Labs,Inc.  
21   NuLev   Hyoscyamine Sulfate   Cima Labs, Inc.  
22   Gaster D  Famotidine   Yamanouchi Pharma Tech. Inc.  
23   Cibalgina DueFast   Ibuprofen   Eurand International  
24   Relivia Flash dose   Tramadol HCl   Fuisz Technology, Ltd.  
25   Hyoscyamine Sulfate ODT   Hyoscyamine Sulfate   KV Pharm.Co.,Inc.  
26.   Abilify Discmelt   Aripiprazole   Otsuka America/Bristol-Myers Squibb  
27   Allegra ODT   Fexofenadine   Sanofi Aventis  
28   Aricept ODT   Donepezil   Eisai Co.  
 
Table 5: Drugs to be promising in corporate in fast dissolving tablets [20-21] 




Aloxiprin, Auranofin, Azapropazone, Benorylate, Diflunisal, Etodolac, Fenbufen, Fenoprofen Calcim, Flurbiprofen, 
Naproxen, Ibuprofen, Indomethacin, Ketoprofen, Meclofenamic Acid, Mefenamic Acid, Nabumetone, Sulindac, 
Oxaprozin, Oxyphenbutazone, Phenylbutazone, Piroxicam. 
Anthelmintics: 
 
Albendazole, Bephenium Hydroxynaphthoate, Cambendazole, Dichlorophen, Iverrnectin, Mebendazole, 
Oxarnniquine, Oxfendazole, Oxantel Embonate, Praziquantel, Pyrantel Embonate, Thiabendazole. 
Anti-Arrhythmic Agents: Amiodarone, Disopyramide, Flecainide Acetate, Quinidine Sulphate. 
Anti-bacterial Agents: Benethamine Penicillin, Cinoxacin, Ciprofloxacin, Clarithromycin, Clofazimine, Cloxacillin, Demeclocycline, 
Doxycycline, Erythromycin, Ethionamide, Imipenem, Nalidixic Acid, Nitrofurantoin, Rifampicin, Spiramycin, 
Sulphabenzamide, Sulphadoxine, Sulphamerazine, Sulphacetamide, Sulphadiazine, Sulphafurazole, 
Sulphamethoxazole, Sulphapyridine, Tetracycline, Trimethoprim. 
Anti-coagulants: 
 
Dicoumarol, Dipyridamole, Nicoumalone, Phenindione. Anti-Depressants: Amoxapine, Ciclazindol, Maprotiline, 
Mianserin, Nortriptyline, Trazodone, Trimipramine Maleate., Acetohexamide, Chlorpropamide, Glibenclamide, 
Gliclazide, Glipizide, Tolazamide, Tolbutamide. 
Anti-Epileptics: 
 
Beclamide, Carbamazepine, Clonazepam, Ethotoin, Methoin, Methsuximide, Phensuximide, 
Methylphenobarbitone, Oxcarbazepine, Paramethadione, Phenacemide, Phenobarbitone, Phenytoin, Primidone, 
Sulthiame, Valproic Acid. 
Anti-Fungal Agents: 
 
Amphotericin, Butoconazole Nitrate, Clotrimazole, Econazole Nitrate, Fluconazole, Fiucytosine, Griseofulvin, 
Itraconazole, Ketoconazole, Miconazole, Natamycin, Nystatin, Sulconazole Nitrate, Terbinafine, Terconazole, 
Tioconazole, Undecenoic Acid. 
Anti-Gout Agents: Allopurinol, Probenecid, Sulphinpyrazone. 
Anti-Hypertensive Agents: 
 
Amlodipine, Carvedilol, Benidipine, Darodipine, Dilitazem, Diazoxide, Felodipine, Guanabenz Acetate, Indoramin, 
Isradipine, Minoxidii, Nicardipine, Nifedipine, Nimodipine, Phenoxybenzamine, Prazosin, Reserpine, Terazosin. 
Anti-Malarials: Amodiaquine, Chloroquine, Chlorproguanil, Halofantrine, Mefloquine, Proguanil, Pyrimethamine, Quinine Sulphate.  
Anti-Migraine Agents: Dihydroergotamine Mesyiate, Ergotamine Tartrate, Methysergide Maleate, Pizotifen Maleate, Sumatriptan Succinate. 
Anti-Muscarinic Agents: 
 
Atropine, Benzhexol, Biperiden, Ethopropazine, Hyoscine Butyl Bromide, Hyoscyarnine, Mepenzolate Bromide, 
Tropicamide, Orphenadrine, Oxyphencylcimine.  
Anti-Neoplastic Agents and 
Immunosuppressants: 
 
Aminoglutethimide, Amsacrine, Azathiopnne, Busulphan, Chlorambucil, Cyclosporin, Dacarbazine, Estramustine, 
Etoposide, Lomustine, Melphalan, Mercaptopurine, Methotrexate, Mitomycin, Mitotane, Mitozantrone, Procarbazine, 
Tamoxifen Citrate, Testolactone. 
Anti Protozoal Agents: 
 
Benznidazole, Clioquinol, Decoquinate, Diiodohydroxyquinoline, Diloxanide Furoate, Dinitolmide, Furzolidone, 
Metronidazole, Nimorazole, Nitrofurazone, Omidazole, Tinidazole. 





Alprazolam, Amyiobarbitone, Barbitone, Bentazeparn, Bromazepam, Bromperidol, Brotizoiam, Butobarbitone, 
Carbromal, Chlordiazepoxide, Chlormethiazole, Chlorpromazine, Clobazam, Clotiazepam, Clozapine, Diazepam, 
Droperidol, Ethinamate, Flunanisone, Flunitrazepam, Fluopromazine, Flupenuiixol Decanoate, Fluphenazine 
Decanoate, Flurazepam, Haloperidol, Lorazepam, Lormetazepam, Medazepam, Meprobamate, Methaqualone, 
Midazolam, Nitrazepam, Oxazepam, Pentobarbitone, Perphenazine Pimozide, Prochlorperazine, Suipiride, 
Temazepam, Thioridazine, Triazolam, Zopiclone. 
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Cardiac-Inotropic Agents: Amrinone, Digitoxin, Digoxin, Enoximone, Lanatoside C, Medigoxin. 
Corticosteroids: 
 
Beclomethasone, Betamethasone, Budesonide, Cortisone Acetate, Desoxymethasone, Dexamethasone, 
Fludrocortisone Acetate, Flunisolide, Flucortolone, Fluticasone Propionatu, Hydrocortisone, Methyl prednisolone, 
Prednisolone, Prednisone, Triamcinolone. 
Diuretics: 
 
Acetazolarnide, Amiloride, Bendrofluazide, Bumetanide, Chlorothiazide, Chlorthalidone, Ethacrynic Acid, Frusemide, 
Metolazone, Spironolactone, Triamterene. 
Anti-Parkinsonian Agents: Bromocriptine Mesylate, Lysuride Maleate. 
Gastro-Intestinal Agents: Bisacodyi, Cimetidine, Cisapride, Diphenoxylate, Domeperidone, Famotidine, Loperamide, Mesalazine, Nizatidine, 
Omeprazole, Ondansetron, Ranitidine, Sulphasaiazine. 
Histamine H,-Receptor 
Antagonists: 
Acrivastine, Astemizole, Cinnarizine, Cyclizine, Cyproheptadine, Dimenhydrinate, Flunarizine, Loratadine, Meclozine, 
Oxatomide, Terfenadine, Triprolidine. 
Lipid Regulating Agents: Bezafibrate, Clofibrate, Fenofibrate, Gemfibrozil, Probucol. 
Local Anaesthetics: Lidocaine. 
Neuro-Muscular Agents: Pyridostigmine. 
Nitrates and Other Anti-
Anginal Agents: 
Amyl Nitrate, Glyceryl Trinitrate, Isosorbide Dinitrate, Isosorbide Mononitrate, Pentaerythritol Tetranitrate. 
 
Nutritional Agents: Betacarotene, Vitamin A, Vitamin B2
Opioid Analgesics: 
, Vitamin D, Vitamin E, Vitamin K.  
 
Codeine, Dextropropyoxyphene, Diamorphine, Dihydrocodeine, Meptazinol, Methadone, Morphine, Nalbuphine, 
Pentazocine. 
Proteins, Peptides and 
Recombinant Drugs: 
 
Insulin (Hexameric/Dimeric/Monomeric Forms), Glucagon, Growth Hormone (Somatotropin), Polypeptides or Their 
Derivatives, (Preferably With A Molecular Weight from 1000 To 300,000), Calcitonins And Synthetic Modifications 
Thereof, Enkephalins, Interferons (Especially Alpha-2 Inter Feron For Treatment Of Common Colds). 
Sex Hormones: 
 
Clomiphene Citrate, Danazol, Ethinyloestradiol, Medroxyprogesterone Acetate, Mestranol, Methyl testosterone, 
Norethisterone, Norgestrel, Oestradiol, Conjugated Oestrogens, Progesterone, Stanozolol, Stiboestrol, Testosterone, 
Tibolone. 
Stimulants: Amphetamine, dexamphetamine, dexfenfluramine, fenfluramine, mhazindol, pemoline. 
*Oral Vaccines:- 
Vaccines designed to prevent or reduce the symptoms of diseases of which the following is a representative Influenza, Tuberculosis, Meningitis, 
Hepatitis, Whooping Cough, Polio, Tetanus, Diphtheria, Malaria, Cholera, Herpes, Typhoid, HIV, Aids, Measles, Lyme Disease, Travellers Diarrhea, 
Hepatitis A, B And C, Otitis Media, Dengue Fever, Rabies, Parainfluenza, Rubella, Yellow Fever, Dysentery, Legionnaires Disease, Toxoplasmosis, Q-
Fever, Haemorrhegic Fever, Argentina Haemorrhagic Fever, Caries, Chagas Disease, Urinary Tract Infection Caused By E.Coli, Pneumoccoccal 
Disease, Mumps, and Chikungunya. 
There are no particular limitations on the amount of these drugs to be mixed as long as it is the usual effective treatment amount. It should be 
around 50% w/w or below of the entire tablet, and is preferably 20% w/w or below.  
 
Approaches for taste masking of fast dissolving tablets [22, 23] 
Fast dissolving tablet, which disintegrate or dissolve in the saliva 
produce a positive or negative taste sensation. Most of the drugs 
have unpalatable taste in which taste masking plays critical role in 
formulating OFDT. The negative taste sensation of drugs can be 
reduced or eliminated by various approaches which include:  
1. Taste masking with flavours and sweeteners. 
2. Taste masking by polymer coating.  
3. Taste masking with ion-exchange resins.  
4. Taste masking by formation of inclusion complexes with 
cyclodextrins.  
5. Miscellaneous Taste-masking approaches.  
Taste masking with flavours and sweeteners 
Maximum patient acceptability with FDT is seen if they provide 
pleasant taste and mouth feel. To provide this property in tablets 
various sweeteners and flavours are employed. Usually sugar-based 
excipients are used as they are highly water soluble and dissolve 
quickly in saliva and provide pleasant taste and mouth feel to the 
final product.  
Mannitol is most widely used excipient in formulating OFDT. 
Aspartame and citric acid are most commonly used along with 
various flavorants such as mint flavour, orange flavour, strawberry 
flavour, peppermint flavour to produce pleasant taste and mouth 
feel.  
Taste masking by polymer coating  
Some of the unpleasant drugs cannot be masked by incorporation of 
sweeteners and flavours, in such cases alternative method of 
masking the taste is by coating the drug. In fact this process retards 
or inhibits dissolution and solubilization of drug, which allows time 
for particles to pass from mouth before taste is perceived in mouth.  
Taste masking by ion-exchange resins [24] 
Drugs are attached to the oppositely charged resin substrate, 
forming insoluble substance or resonate through weak ionic bonding 
so that dissociation of the drug-resin complex does not occur under 
the salivary pH conditions. This suitably masks the unpleasant taste 
and odours of drugs. Drug release from the resin depends on the 
properties of the resin and the ionic environment within the 
gastrointestinal tract (GIT). Drug molecules attached to the resin are 
released by exchanging with appropriately charged ions in the GIT, 
followed by diffusion of free drug molecules.  
Ion-exchange resins are high molecular weight polymers with 
cationic and anionic functional groups. The most frequently 
employed polymeric network is a copolymer of styrene and divinyl 
benzene. Ion-exchange resins are used in drug formulations to 
stabilize the sensitive components, sustain release of the drug, 
disintegrate tablets and mask the taste. Drug can be bound to the 
resin by either repeated exposure of the resin to the drug in a 
chromatographic column or by prolonged contact of resin with the 
drug solution.  
Ion-Exchange Resins can be classified into four major groups:  
 Strong acid cation-exchange resin.  
 Weak acid cation-exchange resin.  
 Strong base anion-exchange resin.  
 Weak base anion-exchange resin.  
Taste masking complexation [24] 
In inclusion complex formation, the drug molecule fits into the cavity 
of a complexing agent, i.e., the host molecule, forming a stable 
complex. The complexing agent is capable of masking the bitter taste 
of drug by either decreasing its oral solubility on ingestion or 
decreasing the amount of drug particles exposed to taste buds, 
thereby reducing the perception of bitter taste. This method is most 
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suitable only for low dose drugs. Vander Waals forces are mainly 
involved in inclusion complexes. Β-cyclodextrin is the most widely 
used complexing agent for inclusion type complexes. It is sweet, 
nontoxic, cyclic oligosaccharide obtained from starch.  
Miscellaneous taste-masking approaches [25] 
 By effervescent agent: 
Effervescent agents have been shown to be useful and advantageous 
for oral administration of drugs and have also been employed for 
use as taste-masking agents for dosage forms that are not dissolved 
in water prior to administration. A chewing gum composition of 
bitter medicament(s) was formulated to supply the medicament(s) 
to the oral cavity for local application or for buccal absorption.  
It comprises a chewing gum base, an orally administrable 
medicament, a taste masking generator of carbon dioxide and 
optionally a taste bud desensitizing composition and other nonactive 
materials, such as sweeteners, flavouring components and fillers. 
The formulations contain the drugs in combination with effervescent 
agents to promote their absorption in the oral cavity and to mask 
their bitter taste.  
 Salt preparation: 
Salt preparation is one of the classical approaches to mask the bitter 
taste of drug by either decreasing solubility or by increasing 
hydrophobicity and thereby reducing contact of bitter drugs with 
taste buds. This approach differs from others to modify the chemical 
composition of the drug substance itself, so as to render it less 
soluble in saliva and thereby less stimulating to the taste buds, or to 
obtain a tasteless or less bitter form.  
Adding alkaline metal bicarbonate such as sodium bicarbonate 
masks the unpleasant taste of water-soluble ibuprofen salts in 
aqueous solution. The bitter taste caffeine may be masked by 
formulating it as a carbonated oral solid preparation using sodium 
bicarbonate, ascorbic acid, citric acid and tartaric acid.  
 Solid dispersion systems: 
Solid dispersion can be defined as the dispersion of one or more 
active ingredients in an inert solid carrier. Solid dispersion of drug 
with the help of polymers, sugar, or other suitable agents, is very 
useful for taste masking. The bitter taste of dimenhydrinate can be 
masked by preparing the solid dispersion of the drug with polyvinyl 
acetate phthalate. 
Mechanism of tablet disintegration  
The tablet breaks to primary particles by one or more of the 
mechanisms listed below: 
By capillary action (Wicking) 
By swelling 
Because of heat of wetting 
Due to release of gases 
By enzymatic action 
Due to disintegrating particle/particle repulsive forces 
Due to deformation. 
By capillary action (Wicking) [26] 
Disintegration by capillary action is always the first step. When we 
put the tablet into suitable aqueous medium, the medium penetrates 
into the tablet and replaces the air adsorbed on the particles, which 
weakens the intermolecular bond and breaks the tablet into fine 
particles. 
Water uptake by tablet depends upon hydrophilicity of the 
drug/excipient and on tabletting conditions. For these types of 
disintegrants, maintenance of porous structure and low interfacial 
tension towards aqueous fluid is necessary which helps in disintegration 
by creating a hydrophilic network around the drug particles. 
By Swelling [26] 
Perhaps the most widely accepted general mechanism of action for 
tablet disintegration is swelling tablet with high porosity show poor 
disintegration due to lack of adequate swelling force. On the other 
hand, sufficient swelling force is exerted in the tablet with low 
porosity. It is worthwhile to note that if the packing fraction is very 
high, fluid is unable to penetrate in the tablet and disintegration is 
again slow down. 
Because of heat of wetting (air expansion) [26] 
When disintegrants with exothermic properties gets wetted, 
localized stress is generated due to capillary air expansion, which 
helps in disintegration of tablet. This explanation however, is limited 
to only a few types of disintegrats and cannot describe the action of 
most modern disintegrating agents. 
 
 
Fig. 1: Wicking mechanism. [26] 
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Fig. 2 the Swelling mechanism [26] 
 
 
Fig. 3: Repulsion mechanism [26] 
 
 
Fig. 4: By deformation [27] 
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Fig. 5: Conceptual mechanism of FDT Disintegrating [27] 
 
Due to release of gases [27] 
Carbon dioxide released within tablets on wetting due to interaction 
between bicarbonate and carbonate with citric acid or tartaric acid. 
The tablet disintegrates due to generation of pressure within the 
tablet. This effervescent mixture is used when pharmacist needs to 
formulate very rapidly dissolving tablets or fast disintegrating tablet. 
As these disintegrants are highly sensitive to small changes in 
humidity level and temperature, strict control of environment is 
required during manufacturing of the tablets. The effervescent blend 
is either added immediately prior to compression or can be added in 
to two separate fraction of formulation. 
By enzymatic reaction [27] 
Here, enzymes present in the body act as disintegrants. These 
enzymes destroy the binding action of binder and helps in 
disintegration. Actually due to swelling, pressure exerted in the 
outer direction or radial direction, it causes tablet to burst or the 
accelerated absorption of water leading to an enormous increase in 
the volume of granules to promote disintegration. 
Due to disintegrating particle/particle repulsive forces [27] 
Another mechanism of disintegration attempts to explain the 
swelling of tablet made with non swellable disintegrants. Guyot-
Hermann has proposed a particle repulsion theory based on the 
observation that non-swelling particle also cause disintegration of 
tablets The electric repulsive forces between particles are the 
mechanism of disintegration and water is required for it. 
Researchers found that repulsion is secondary to wicking.  
Due to deformation [27] 
Hess had proved that during tablet compression, disintegranted 
particles get deformed and these deformed particles get into their 
normal structure when they come in contact with aqueous media or 
water. Occasionally, the swelling capacity of starch was improved 
when granules were extensively deformed during compression. This 
increase in size of the deformed particles produces a breakup of the 
tablet. This may be a mechanism of starch and has only recently 
begun to be studied. 
FUTURE PROSPECTS AND RESEARCH TRENDS IN FDTS [28] 
There are several biopharmaceutical advantages such as improved 
efficiency over conventional dosage forms for Fast disintegrating 
tablets. For example, they require smaller amounts of active 
ingredient to be effective, improve absorption profiles, and offer 
better drug bioavailability than regular tablets and capsules. There 
are still many aspects to improve in the FDT formulations. The 
disintegration times of most FDTs on the market are acceptable i.e., 
less than 60 seconds but certainly there is a room for improvement. 
Because the disintegration time is related to other formulation 
variables, a balance has to be maintained between shortening the 
disintegration time and other tablet properties. The tablet hardness, 
friability, and stability can be further improved to such a level that 
multi-tablet packaging in conventional bottles becomes a norm. 
There may be no magic solution to this, but more effective use of 
existing taste masking technologies is expected to alleviate the 
problems associated with taste masking. The future of FDTs lies in 
the development of FDTs with controlled release properties. Despite 
advances in the FDT technologies, formulation of hydrophobic drugs 
is still a challenge, especially when the amount of drug is high. The 
low dose drugs, such as Loratadine with 10 mg dose, pose little 
problem, but as the dose increases, the formulation sacrifices its fast 
disintegrating property. A new technology is being developed to 
incorporate higher doses of hydrophobic drugs without affecting the 
fast disintegrating property too severely. If one FDT can deliver 
drugs with short half-lives for 12-24 hours, it would be a quantum 
improvement in the FDT technology. The added convenience and 
compliance of such formulations would be enormous. In addition, 
the ability to formulate drugs in large doses will bring another 
important technological advance. In general, the FDT formulations 
require large amounts of excipients, and having large doses of drug 
will only make the final formulation too big to handle. An FDT 
formulation that would require fewer excipients than the drug itself 
would be a break through. While the problems to be solved are not 
easy, the history suggests that it is just a matter of time before they 
are solved. 
The safety and efficacy profile of drugs in orodispersible tablet is 
same like their conventional tablet dosage form. Based on 
conventional techniques, new techniques are developed like Zydis, 
Wow Tab, Flashtab technology and many more, which leads to 
getting a patent and new market strategy for orodispersible tablets. 
This dosage form are gaining market share day by day and becoming 
a better choice of acceptance. 
CONCLUSION 
Fast disintegrating tablets have better patient acceptance and offer 
improved biopharmaceutical properties, improved efficacy and 
better safety as compared with conventional oral dosage forms. By 
using new manufacturing technologies, many drugs can be 
formulated in the form of fast disintegrating tablets to provide the 
advantages of liquid medication in the form of solid preparation. 
FDT need to be formulated for pediatric, geriatric, bedridden, 
psychotic patients, for those patients who are busy in travelling, 
patients who are may not have access to water. The clinical studies 
show FDTs can improve patient compliance, provide a rapid onset 
time of action, and increase bioavailability. The development of a 
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fast-dissolving tablet also provides an opportunity for a line 
extension in the market place; a wide range of drugs (e.g., 
neuroleptics, cardiovascular drugs, analgesics, antihistamines, and 
drugs for erectile dysfunction) can be considered candidates for this 
dosage form. Pharmaceutical marketing is another reason for the 
increase in available fast dissolving/ disintegrating products. As a 
drug entity nears the end of its patent life, it is common for 
pharmaceutical manufacturers to develop a given drug entity in a 
new and improved dosage form. Fast dissolving/ disintegrating 
tablet formulations are similar to many sustained release 
formulations that are now commonly available. An extension of 
market exclusivity, which can be provided by a fast-
dissolving/disintegrating dosage form, leads to increased revenue, 
while also targeting underserved and under-treated patient 
populations. Although the cost to manufacture these specialized 
dosage forms exceeds that of traditional tablets, this additional cost 
is not being passed on to the consumer. Due to the constraints of the 
current FDDT technologies as highlighted above, there is an unmet 
need for improved manufacturing processes for fast dissolving 
tablets that are mechanically strong, allowing ease of handling and 
packaging and with production costs similar to that of conventional 
tablets. To fulfill these medical needs, formulators have devoted 
considerable effort to developing a novel type of tablet dosage form 
for oral administration, one that disintegrates and dissolves rapidly 
in saliva without the need for drinking water. 
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